Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.6.3565

Treatment Outcome of Palliative Chemotherapy in Inoperable Cholangiocarcinoma in Thailand  

Butthongkomvong, Kritiya (Medical Oncology Unit, Udonthani Cancer Hospital)
Sirachainan, Ekaphop (Medical Oncology Unit, Ramathibodi Hospital)
Jhankumpha, Supattra (Medical Oncology Unit, Udonthani Cancer Hospital)
Kumdang, Surang (Medical Oncology Unit, Udonthani Cancer Hospital)
Sukhontharot, On-Usa (Cancer Registry Unit, Udonthani Cancer Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.6, 2013 , pp. 3565-3568 More about this Journal
Abstract
Background: Cholangiocarcinoma is the most common cancer in males in Thailand. The outcome is poor although systemic chemotherapy has been used in attempts to improve disease control, quality of life and prolong survival in patient with unresectable and advanced disease. Materials and Methods: In this retrospective study the medical records of all patients diagnosed as having unresectable and metastatic cholangiocarcinoma and receiving systemic chemotherapy at Udonthani Cancer Hospital during January 2007 to December 2010 were reviewed. Results: Among the total of 105 patients, 21 received gemcitabine-based chemotherapy and 84 5FU-based chemotherapy. Most received platinum doublet regimens. 5FU-based regimens yielded an overall response rate (tumor control) of 23.8% and a median survival of 7.2 months while gemcitabine-based regimens yielded an overall response rate (tumor control) 19.1% and a median survival of 10.0 months. Conclusions: Tumor control and survival of patient with advanced cholangiocarcinoma treated with gemcitabine-based and 5FU-based chemotherapy do not markedly differ.
Keywords
Unresectable; inoperable; metastatic cholangiocarcinoma; chemotherapy; outcome;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Thongprasert S, Napapan S, Charoentum C, et al (2005). Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol, 16, 279-81.   DOI   ScienceOn
2 Valle J, Wasan H, John E, et al (2009). Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer, 101, 621-7.   DOI   ScienceOn
3 Valle J, Wasan H, Palmer DH, et al (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 362, 1273-81.   DOI   ScienceOn
4 Yonemoto N, Furuse J, Okusaka T, et al (2007). A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol, 37, 843-51.   DOI   ScienceOn
5 Anderson CD, Wright PC, Berlin J, et al (2004). Diagnosis and treatment of cholangiocarcinoma. Oncologist, 9, 43-57.
6 Chaiyut C, Thongprasert S, Busyamas C, et al (2007). Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma. World J Gastroenterol, 13, 2852-4.
7 Chaiwerawattana A, Sukarayodhin S, Karalak A, et al (2011). Screening, diagnosis and treatment of liver cancer and bile duct cancer. 2nd ed. National cancer Institute, Thailand
8 de Groen PC, Gores GJ, LaRusso NF, et al (1999). Biliary tract cancers. N Engl J Med, 341, 1368-78.   DOI   ScienceOn
9 Hezel AF, Zhu AX (2008). Systemic therapy for biliary tract cancers. Oncologist, 13, 415-23.   DOI   ScienceOn
10 Glimelius B, Hoffman K, Sjoden P-O, et al (1996). Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol, 7, 593-600.   DOI   ScienceOn
11 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
12 Jongha P, Myung-Hwan K, Kyu-pyo Kim, et al (2009). Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver, 3, 298-305.   DOI   ScienceOn
13 Khan SA, Davidson BR, Goldin R, et al (2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut, 51, 1-9.   DOI
14 Khuhaprema T, Srivatanakul P, Attasara P, et al (2010). Cancer incidence in Thailand, liver and bile duct. Cancer in Thailand, 5, 31-4
15 Khuntikao N (2005). Current concept in management of cholangiocarcinoma. Srinagarind Med J, 20, 143-9.
16 Murad A, Mark JW, Michele M (2009). Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol, 15, 4240-62.   DOI   ScienceOn
17 Sararat C (2010). Hospital based cancer registry 2009. Cancer registry unit, Udonthani cancer center, Thailand
18 Siegel R, Naishadham D, Jemal A(2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.   DOI   ScienceOn
19 Thongprasert S (2005). The role of chemotherapy in cholangiocarcinoma. Ann Oncol, 16, 93-6.